For patients with prostate disorders, this is good news for you. The experts in this field believe can prescribe drugs to treat prostate cancers that contain Abiraterone starting next year.
Abiraterone has been making headlines since two years ago, when this element was tested in patients with cancer spreads throughout the body. The results showed that cancer cells shrink as much as 80 percent. The future of this drug can reduce the pain perceived and touted as the biggest breakthrough in the field for 60 years
Now, Abiraterone continue to be developed further and a larger trial is underway. If the test is successful, Abiraterone could be prescribed for patients with advanced cancer, start at least next year, so that will give hope to live longer with their families.
Abiraterone practically homemade drugs, found by scientists funded by Cancer Research UK in collaboration with the Institute for Cancer Research in London's Royal Marsden Hospital.
How it works is by blocking abiraterone hormone testosterone, including those created by the tumor cells themselves so they no longer trigger cancer growth.
In a recent study, Abiraterone given in pill form to 47 patients with an advanced stage prostate cancer who are tired with all the choices of other treatments, including drug called docetaxel.
"Drug docetaxel is important but can only sustain an average life of two to three months only. So there is an urgent need to improve choice for patients with end stage. Abiraterone could undermine stable tumor cells to an average of almost six months. This is the result that very impressive, "says Johann de Bono was one of the researchers.
According to reports the Journal of Clinical Oncology, doctors took blood samples of patients, and total PSA (Prostate Specific Antigen) in the blood are measured in laboratories. PSA is produced by the body and can be used to detect the disease. Sometimes this is called a sign or signs of tumor biology. PSA level was found in 75 percent of the men, but any mild side effects will be easily treated.
"This finding is very important because it offers new hope for people who can quickly find a way out so they stopped reacting tumor treatment," said Dr Helen Rippon from Prostate Cancer Charity, which is also funding research of this drug.
Prostate cancer is most common in the UK and is the second highest killer, after lung cancer. Approximately 35 thousand people per year being diagnosed with cancer type, and 12 thousand of them could not be saved.
There are two types of prostate cancer, non-aggressive and aggressive. Two-thirds of the patients suffered from a kind of non-aggressive and often can lead a healthy life. Patients with aggressive version, usually dies within 18 months after diagnosis. But, Abiraterone can shrink the tumors aggressively, although the effect does not last forever.
0 comments:
Post a Comment